Tag Archives: “booster” vaccine

Factbox – Latest on the worldwide spread of the coronavirus

(Reuters) – Moderna Inc said on Monday its COVID-19 vaccine generated a strong immune response in children aged six to 11 years and that it plans to submit the data to global regulators soon.

EUROPE

* The European Union’s drug regulator said it has concluded in its review that Moderna’s COVID-19 booster vaccine may be given to people aged 18 years and above, at least six months after the second dose.

** Russia reported a record high number of daily COVID-19 cases and some central European countries imposed fresh restrictions on Monday, as a new wave of the pandemic gathered pace.

* Spain reached the grim milestone of 5 million COVID-19 cases during the pandemic.

* The Dutch government may impose new coronavirus restrictions to reduce pressure on hospitals struggling to deal with a swelling number of COVID-19 patients.

AMERICAS

* U.S. President Joe Biden on Monday signed an order imposing new vaccine requirements for most foreign national air travelers and lifting severe travel restrictions on China, India and much of Europe effective Nov. 8.

* The Biden administration said it will invest $70 million to boost the availability and lower costs of rapid, over-the-counter COVID-19 tests in the United States.

* Venezuela reopened public schools and universities which serve more than 11 million students, though some schools remained closed for repairs or because of lack of staff.

ASIA-PACIFIC

* China’s latest COVID-19 outbreak is increasingly likely to spread further, a health official said on Sunday, as authorities urged all regions to step up monitoring and called for a reduction in travel across provinces.

* Competitors in the Beijing 2022 Winter Olympics will be subject to daily tests for COVID-19 and will be required to remain in a closed loop that includes transport between the various games venues.

* Indonesia is “finalizing” a deal with Merck & Co to procure its experimental antiviral pills to treat COVID-19 ailments.

MIDDLE EAST AND AFRICA

* South Africa’s Aspen Pharmacare is aiming to ramp up its COVID-19 vaccine manufacturing capacity to 1.3 billion doses a year by February 2024, up from a current annual output of around 250 million doses, the company’s CEO told Reuters.

* Namibia will suspend its rollout of Russia’s Sputnik V COVID-19 vaccine, days after the drugs regulator in neighboring South Africa flagged concerns about its safety for people at risk of HIV.

MEDICAL DEVELOPMENTS

* Scientists at the U.S. Food and Drug Administration said the likely benefits of giving the Pfizer/BioNTech COVID-19 vaccine to 5 to 11 year old’s clearly outweigh the risks of rare cases of heart inflammation.

* COVID-19 patients who require surgery appear to face fewer complications if they have previously been vaccinated against the flu, new data suggest.

* U.S. drugmaker Merck & Co Inc said the European Union’s drug regulator has initiated a real-time review of its experimental COVID-19 antiviral drug for adults.

ECONOMIC IMPACT

* Global equity markets rose, while U.S. Treasury yields dipped as investors were buoyed by a better-than-expected U.S. corporate earnings season that kicks into gear this week.

* The European Union disbursed 600 million euros ($698 million) to Ukraine, the second tranche of an aid program to help its eastern European neighbor through the economic shock of the pandemic.

(Compiled by Aditya Soni and Uttaresh. V; Editing by Anil D’Silva and Arun Koyyur)

Vaccines effective vs variants despite diminished antibodies; kids may be as contagious as adults

By Nancy Lapid

(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Vaccines protect against variants despite diminished antibodies

The one-dose Johnson & Johnson COVID-19 vaccine and the two-dose vaccine from Pfizer and BioNTech appear to protect against worrisome coronavirus variants despite diminished levels of antibodies that can neutralize the newer versions of the virus, two studies in the journal Nature suggest. The authors of both studies said other immune responses may be compensating. In one study, published on Wednesday, researchers experimented with blood from people who had received the J&J vaccine two months earlier. Compared to their levels of neutralizing antibodies against the virus that was circulating early in the pandemic, levels of neutralizing antibodies against variants first identified in the UK, South Africa, Brazil and California were about three-fold lower. However, the researchers observed other “robust” immune activity and cells whose responses against the variants were undiminished. In clinical trials, the researchers noted, the J&J vaccine protected against symptomatic COVID-19 in South Africa and in Brazil, where most cases were caused by the variants. Its effectiveness in these regions raises the possibility that these other immune responses may be contributing to protection, coauthor Dr. Dan Barouch of Beth Israel-Deaconess Medical Center in Boston, said in a statement. In a separate study using blood from recipients of the Pfizer/BioNTech shots, levels of antibodies that could neutralize concerning variants first identified in India and Nigeria were lower compared to an earlier version of the virus, researchers reported on Thursday. Still, they reported “robust neutralization” of all tested variants. Neutralizing antibodies, the researchers said, do not reflect all potentially protective vaccine responses.

Children with COVID-19 may be as contagious as adults

In a community-based study of COVID-19 patients who were not hospitalized, U.S. researchers found that children and adults with symptoms had similar viral loads, which suggests children can be just as contagious as grownups. “There has been a lot of debate around school openings and about whether children could transmit the virus and we thought this study could help answer some of these questions,” said Dr. Helen Chu of the University of Washington, who coauthored a report published on Friday in JAMA Pediatrics. Her team looked at 123 children and 432 adults with COVID-19 and found that nearly all of the adults had symptoms, compared to about two-thirds of the children. “Overall, people with symptoms had higher virus levels than people without symptoms,” Chu said. “However, when you looked within these groups – those with symptoms or those without – viral load was the same whether you were a child or an adult.” She noted that swab tests were only done once, so researchers cannot be sure they took place when patients’ viral loads were highest. But overall, she said, children in the community with SARS-CoV-2 infection can have virus levels similar to adults and can transmit it to others.

Oral booster vaccine shows promise in animal tests

An experimental “booster” vaccine against COVID-19 that is taken by mouth has yielded promising early results in studies in rats, Israeli researchers said. The oral vaccine, MigVax-101, targets multiple sites on the coronavirus. Along with the spike protein on the surface of the virus, which is the target of currently available vaccines, the oral vaccine also targets two sites on the virus shell, which encapsulates its genetic material. In laboratory experiments, rats that had received two doses of vaccines that targeted the spike protein were given the oral booster. “These rats developed a much higher level of antibodies for neutralizing the disease than did control group rats that received a placebo or a third injection of the (original) vaccine,” said David Zigdon of MIGAL Galilee Research Institute Ltd, who coauthored a report posted on Wednesday on bioRxiv ahead of peer review. If it is proven safe for humans, an oral vaccine might trigger strong immune responses in the mucosal surfaces of the mouth and upper respiratory tract, which would in turn help block viral entry, the researchers speculated. An oral vaccine could be particularly useful in developing countries because it would avoid the need for distribution of needles and could be self-administered.

(Reporting by Nancy Lapid and Christine Soares; Editing by Bill Berkrot)